An interventional study of Virtual Reality-Based Branching Scenario Education and Tablet-Based Branching Scenario Education in Coronary Arterial Disease (CAD), sponsored by Abant Izzet Baysal University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Abant Izzet Baysal University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies in Coronary Artery Disease with a site in Turkey — 33 open to participants now, 42 under way, 4 of them phase 3. Coronary Artery Disease · Turkey.
Among the 137 studies in Coronary Artery Disease with a site in Turkey, this one is the 53rd largest by planned enrollment of the 71 interventional ones that give a count, is one of 25 that started in 2026, is one of 58 with no phase, reaches primary completion later than 19 of the 41 other live ones, and was the 126th registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →33 of the 137 studies in Coronary Artery Disease with a site in Turkey are open now. Recruiting first, the newest first:
Adiyaman University · Sites in Turkey
Ages 18+
Elzem SEN · Sites in Turkey
Ages 18–80
Elzem SEN · Sites in Turkey
Ages 18–80
TC Erciyes University · Sites in Turkey
Ages 18–50 · Women only
Uludag University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 11 · Phase 4 1
First in 2004; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 70 across the 71 interventional studies, 167 across the 66 observational. Of the 82 that completed or were terminated, 10 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 137 have an industry lead sponsor. The 10 most frequent:
Abant Izzet Baysal University is the lead sponsor of 250 studies on the registry; 59 are open to participants now.
Abant Izzet Baysal University has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
17 of the studies in Coronary Artery Disease with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07768020Munzur UniversityEffect of Eye Mask Use on Sleep Quality and Delirium After CABG Surgery | 2026-11-15 |
| NCT07722637TC Erciyes UniversityThe Effect of Cardiac Rehabilitation on Ferroptosis in Patients With Coronary Artery Disease | 2026-11-15 |
| NCT07051473Istanbul University - CerrahpasaRelationship Between Coronary CT Angiography Findings and Prognosis Of Patients Undergoing PCI | 2026-12 |
| NCT07825376Abant Izzet Baysal UniversityBranching Scenario-Based Education in Coronary Artery Disease | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 137 studies in Coronary Artery Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to evaluate the effects of nurse-led branching scenario-based education delivered through virtual reality and tablet on cardiovascular disease risk awareness and adherence to antiplatelet medication in patients with coronary artery disease. Participants will be randomly assigned to a virtual reality education group, a tablet-based education group, or a control group receiving routine hospital education. Cardiovascular disease risk awareness and medication adherence will be assessed before and after the educational intervention and during follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants in the control group receive routine clinical education.
Participants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a virtual reality headset.
Behavioral: Virtual Reality-Based Branching Scenario Education
Participants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a tablet and headphones.
Behavioral: Tablet-Based Branching Scenario Education
Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a virtual reality (VR) headset. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.
Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a tablet. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.
cardiovascular disease risk awareness assessment scale score
Change in cardiovascular disease risk awareness, assessed using the Turkish validated 22-item Cardiovascular Disease Risk Awareness Assessment Scale (CVD-RAAS). The knowledge domain score ranges from 0 to 8, with higher scores indicating higher knowledge about myocardial infarction and stroke. The total score for the 14-item Likert-type awareness subscales ranges from 14 to 56, with higher scores indicating greater awareness of cardiovascular disease risks, healthier dietary intentions, and higher readiness for behavioral change.
Time frame: baseline and immediately after the educational intervention
medication adherence report scale score
Change in medication adherence, assessed using the Turkish validated 5-item Medication Adherence Report Scale (MARS-5). Each item is scored on a 5-point Likert scale (1 = always to 5 = never). Total scores range from 5 to 25, with higher scores indicating greater medication adherence.
Time frame: Baseline, immediately after the intervention, and 3 months follow-up
Cardiovascular Disease Risk Awareness Assessed by the Cardiovascular Disease Risk Awareness Assessment Questionnaire
Cardiovascular disease risk awareness will be assessed using the Turkish version of the Cardiovascular Disease Risk Awareness Assessment Questionnaire (CDRAAQ), a 22-item instrument consisting of an 8-item knowledge section and three subscales: perceived risk of heart attack/stroke, healthy eating intentions, and perceived benefits and intentions to change. The knowledge items are scored as correct or incorrect, with each correct response receiving 1 point. The subscale items are rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree), with reverse scoring applied where appropriate. Higher scores indicate greater cardiovascular disease risk awareness, greater knowledge of heart attack and stroke, and greater readiness for health-related behavioral change.
Time frame: Baseline, immediately after the intervention, and 3 months after the intervention.
Plan to share: No — for the protection of personal data
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.
Of 753 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 3 months is below that.
Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abant Izzet Baysal University →